Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the eylea market right now?

The market size for eylea has been witnessing consistent growth over the years. This upward trend is projected to continue as the market size is expected to increase from $8.09 billion in 2024 to $8.49 billion in 2025, with a compound annual growth rate (CAGR) of 4.9%. Various factors have contributed to growth in the past, including the prevalence of diabetic macular edema (DME), the clinical effectiveness and safety profile of eylea, competition with other anti-VEGF therapies, approval for different retinal conditions, and a shift towards intravitreal injections.

How fast Is the eylea market expected to grow, and what’s its future value?

The eylea market is predicted to experience significant expansion in the forthcoming years. By 2029, it is projected to reach a value of $10.75 billion, with a compound annual growth rate (CAGR) of 6.1%. This escalation during the forecast period is ascribed to the rise of therapeutic indications, the influx of biosimilar competition, heightened awareness and diagnosis, tangible evidence and post-market research, as well as the patient’s favor towards fewer injections. Within this prediction period, the major trends to look out for are advancements in the realm of imaging technologies, the proliferation of telemedicine and remote monitoring, patient assistance programs, progress in drug delivery technologies, retinal imaging breakthroughs, and the conduction of clinical trials for new indications.

Get your eylea market report here!

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

What are the leading drivers of growth in the eylea market?

The escalating occurrence of eye disorders is anticipated to spur the growth of the Eylea market. Eye disorders, often without early symptoms, hamper the normal functioning of the eye and impair vision. Eylea is effective in treating a variety of eye disorders, including wet age-related macular degeneration (AMD) and glaucoma, which damage the retina or macula, affecting vision. Eylea functions by prohibiting a protein that forms new, vulnerable blood vessels, and reduces the swelling of the retina caused by blocked blood vessels. For example, as per the BrightFocus Foundation, a US-based nonprofit focused on promoting research and support for macular degeneration and glaucoma, in October 2022, the number of glaucoma patients worldwide stood at 80 million, with an expected surge to over 111 million by 2040. Consequently, the growing occurrence of eye diseases is bolstering the Eylea market.

What are the key segments defining the eylea market?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

Who are the key players steering the development of the eylea market?

Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

What emerging trends are influencing the growth of the eylea market?

The increasing popularity of research and innovation is a key trend observed in the eylea market. Major industry figures make it their main objective to develop innovative technical solutions. For example, in August 2023, Regeneron Pharmaceuticals, Inc., a global biotechnology corporation based in the United States and dedicated to creating treatments for severe diseases, secured US FDA approval for Eylea HD (aflibercept) injection 8 mg. This medication is developed to treat patients suffering from wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The administration guideline begins with a schedule of every four weeks for the initial three months for all conditions, which is then modified to every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9155

Which regions are most influential in expanding the eylea market?

North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Network Engineering Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/network-engineering-services-global-market-report

Product Engineering Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/product-engineering-services-global-market-report

IoT in Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/iot-in-manufacturing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: